Ars Pharmaceuticals, Inc. (SPRY) — 8-K Filings

8-K Filings (14)

• ARS Pharmaceuticals Files 8-K on New Agreement and Obligation — Sep 29, 2025 Risk: medium
  On September 29, 2025, ARS Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement and a direct financial obligation. The filing ind
• Jazz Pharma to Acquire ARS Pharma for $1B — Aug 28, 2025 Risk: medium
  ARS Pharmaceuticals, Inc. announced on August 13, 2025, that it has entered into a definitive agreement to be acquired by Jazz Pharmaceuticals plc. The transact
• ARS Pharmaceuticals Files 8-K on Shareholder Vote Matters — Jun 26, 2025 Risk: low
  ARS Pharmaceuticals, Inc. filed an 8-K on June 26, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 25, 2025. The
• ARS Pharmaceuticals Enters Material Definitive Agreement — May 2, 2025 Risk: medium
  On May 2, 2025, ARS Pharmaceuticals, Inc. filed an 8-K report indicating the entry into a Material Definitive Agreement. The filing does not provide specific de
• ARS Pharmaceuticals Files 8-K Report — Mar 5, 2025 Risk: low
  On March 5, 2025, ARS Pharmaceuticals, Inc. filed an 8-K report. The filing pertains to 'Other Events' and was submitted on the same date. The company, formerly
• ARS Pharma Files 8-K on Financials — Jan 13, 2025 Risk: low
  ARS Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also included Regulation
• ARS Pharmaceuticals Enters Material Definitive Agreement — Nov 12, 2024 Risk: medium
  On November 9, 2024, ARS Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The filing does not disclose specific details of the agreement, the
• ARS Pharmaceuticals Enters Material Definitive Agreement — Oct 15, 2024 Risk: medium
  ARS Pharmaceuticals, Inc. entered into a Material Definitive Agreement on October 8, 2024. The filing does not disclose specific details of the agreement, such
• ARS Pharmaceuticals Enters Material Definitive Agreement — Sep 23, 2024 Risk: medium
  On September 17, 2024, ARS Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The filing does not disclose specific details of the agreement, s
• ARS Pharmaceuticals Files 8-K — Aug 12, 2024 Risk: low
  ARS Pharmaceuticals, Inc. filed an 8-K on August 12, 2024, reporting on events that occurred on August 9, 2024. The filing primarily concerns Regulation FD disc
• ARS Pharmaceuticals Files 8-K — Jun 28, 2024 Risk: low
  ARS Pharmaceuticals, Inc. filed an 8-K on June 28, 2024, reporting on events that occurred on June 27, 2024. The filing includes information related to Regulati
• ARS Pharmaceuticals Reports Security Holder Vote — Jun 21, 2024 Risk: medium
  ARS Pharmaceuticals, Inc. filed an 8-K on June 21, 2024, reporting on a matter submitted to a vote of its security holders on June 20, 2024. The filing does not
• ARS Pharmaceuticals Files 8-K — May 10, 2024 Risk: low
  ARS Pharmaceuticals, Inc. filed an 8-K on May 10, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
• ARS Pharmaceuticals Files 8-K — Mar 7, 2024 Risk: low
  ARS Pharmaceuticals, Inc. filed an 8-K on March 7, 2024, to report on its results of operations and financial condition, as well as to provide Regulation FD dis

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX